Virtu KCG Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Virtu KCG Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,400	Closed	-$354K	–	3623
2015 Q4	$354K	Sell	5,400 -15,500	-74%	-$958K	0.01%	1954
2015 Q3	$1.18M	Buy	20,900 +9,500	+83%	+$616K	0.02%	753
2015 Q2	$674K	Buy	11,400 +7,600	+200%	+$469K	0.01%	1220
2015 Q1	$237K	Sell	3,800 -13,600	-78%	-$791K	﹤0.01%	2195
2014 Q4	$1M	Buy	17,400 +10,600	+156%	+$591K	0.02%	947
2014 Q3	$366K	Sell	6,800 -9,400	-58%	-$498K	0.01%	2072
2014 Q2	$849K	Sell	16,200 -86,000	-84%	-$4.4M	0.01%	1351
2014 Q1	$5.4M	Buy	102,200 +32,600	+47%	+$1.51M	0.07%	238
2013 Q4	$2.79M	Buy	69,600 +57,200	+461%	+$2.25M	0.03%	464
2013 Q3	$468K	Buy	+12,400	New	+$484K	0.01%	2085

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtu KCG Holdings's TEVA Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 55,676 shares — an estimated $1.79M sold.

Virtu KCG Holdings first reported a position in TEVA in Q3 2013 and held it in 14 quarters. The position peaked at $8.16M in Q3 2016. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Virtu KCG Holdings reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 55,676 Teva Pharmaceuticals shares in Q2 2017, an estimated $1.79M.
Virtu KCG Holdings first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 14 quarters.
Virtu KCG Holdings's Teva Pharmaceuticals position peaked at $8.16M in Q3 2016.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.